BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Taiwan hosts international symposium to explore potentials of therapeutic biomolecules

May 27, 2025 | News

The 2025 ATC Antibody Drug and 20th Advanced Biomedical Science New Knowledge Symposium convening



Taiwan's National Biotechnology Research Park (NBRP) hosted the 2025 Antibody Therapeutic & Frontiers in Biomedical Sciences Conference on May 26-27. Designed to accelerate next-generation biomedical breakthroughs, the event serves as a forum for sharing research and establishing meaningful collaborations.

This conference strengthened its role as a platform for fostering academic-industry collaboration and sharing cutting-edge biomedical knowledge. Academia Sinica Biomedical Translation Research Center (BioTReC), Taiwan Antibody Association (TAA), and Taipei Professor Lin Rongyao Academic Education Foundation co-organized the event.

Dr. Han-Chung Wu, President of the Taiwan Antibody Association and Director of the Biomedical Translation Research Center at Academia Sinica, at the Translational Biotechnology Research Park in Taipei, launched the 2025 Antibody Therapeutics & 20th Frontiers in Biomedical Sciences Conference.

The sessions explored applications in mRNA vaccines, cell therapies, and antibody-drug conjugates (ADCs), which address medical needs, analyze global market trends, and analyze international market trends. Distinguished experts, professionals and scholars from around the world presented groundbreaking biomedical research.

A variety of emerging technologies were discussed at the conference, including those related to immunology, oncology, and advanced cell therapies. The discussions were extended from immunomodulation to cellular interventions that are designed to enhance the safety and scalability of CAR and TCR T-cell therapies.

Furthermore, by focusing on overcoming long-standing clinical challenges, the next breakout sessions demonstrated technologies aimed at enhancing therapeutic precision, reducing immunogenicity, and improving safety. With selective activation, some innovations were designed to minimize adverse effects and enhance therapeutic targeting, representing a

significant advance in the development of safer, more effective biologics.

The focus of the second day session was on innovative biomedical applications within the biotechnology industry. Scholars with distinguished academic backgrounds shared their research insights and academic paths during a half-day program that offered perspectives for emerging voices. A major focus of the conference was the advancement of antibody-based technologies and Taiwan's position as one of the world's leading centers of biomedical research and development.